Humankind Investments LLC Lowers Stock Holdings in Cardinal Health, Inc. $CAH

Humankind Investments LLC trimmed its stake in Cardinal Health, Inc. (NYSE:CAH) by 4.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,805 shares of the company’s stock after selling 172 shares during the period. Humankind Investments LLC’s holdings in Cardinal Health were worth $524,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Greykasell Wealth Strategies Inc. purchased a new stake in shares of Cardinal Health in the 1st quarter worth approximately $26,000. Bellwether Advisors LLC purchased a new stake in shares of Cardinal Health in the 4th quarter worth approximately $32,000. Tompkins Financial Corp lifted its position in shares of Cardinal Health by 106.7% in the 1st quarter. Tompkins Financial Corp now owns 248 shares of the company’s stock worth $34,000 after purchasing an additional 128 shares during the period. Itau Unibanco Holding S.A. bought a new position in shares of Cardinal Health during the 4th quarter worth approximately $36,000. Finally, GW&K Investment Management LLC raised its stake in shares of Cardinal Health by 113.4% during the 1st quarter. GW&K Investment Management LLC now owns 271 shares of the company’s stock worth $37,000 after acquiring an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Cardinal Health Stock Performance

Shares of NYSE CAH opened at $149.0390 on Wednesday. The company’s fifty day moving average price is $159.47 and its 200 day moving average price is $144.94. Cardinal Health, Inc. has a 1 year low of $106.54 and a 1 year high of $168.44. The company has a market capitalization of $35.59 billion, a PE ratio of 23.11, a price-to-earnings-growth ratio of 1.26 and a beta of 0.67.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings results on Tuesday, August 12th. The company reported $2.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.05. Cardinal Health had a net margin of 0.70% and a negative return on equity of 74.45%. The firm had revenue of $60.16 billion for the quarter, compared to the consensus estimate of $60.91 billion. During the same period in the prior year, the firm posted $1.84 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Cardinal Health has set its FY 2026 guidance at 9.300-9.500 EPS. On average, equities analysts expect that Cardinal Health, Inc. will post 7.95 EPS for the current year.

Cardinal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be issued a dividend of $0.5107 per share. The ex-dividend date of this dividend is Wednesday, October 1st. This represents a $2.04 dividend on an annualized basis and a yield of 1.4%. Cardinal Health’s dividend payout ratio is 31.63%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Citigroup restated a “neutral” rating and set a $170.00 price target (up previously from $157.00) on shares of Cardinal Health in a research note on Friday, June 13th. Wells Fargo & Company restated an “overweight” rating and set a $185.00 price target (up previously from $183.00) on shares of Cardinal Health in a research note on Wednesday, August 13th. Bank of America upped their price target on shares of Cardinal Health from $165.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, June 10th. Leerink Partners cut their price target on shares of Cardinal Health from $188.00 to $186.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th. Finally, Morgan Stanley restated an “overweight” rating on shares of Cardinal Health in a research note on Tuesday, August 12th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $163.20.

Insider Activity

In related news, CEO Jason M. Hollar sold 107,705 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $148.90, for a total transaction of $16,037,274.50. Following the sale, the chief executive officer directly owned 235,901 shares of the company’s stock, valued at approximately $35,125,658.90. This represents a 31.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Stephen M. Mason sold 41,575 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $148.82, for a total transaction of $6,187,191.50. Following the sale, the chief executive officer directly owned 26,085 shares in the company, valued at $3,881,969.70. This trade represents a 61.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 235,775 shares of company stock valued at $35,102,939 in the last three months. Corporate insiders own 0.09% of the company’s stock.

Cardinal Health Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.